Is Alpha Teknova, Inc. (TKNO) a Buy, Sell, or Hold?
NASDAQ : TKNO
Alpha Teknova, Inc. — News
$6.72 USD
$0.26 (4.02%)
- Volume
- 175.51K
- Average Volume
- 154.8K
- Market Capitalization
- $360.29M
- P/E Ratio
- -21.33
- Dividend Yield
- 0.00%
- Price Target
- $7.50
- Year High
- $6.92
- Year Low
- $1.91
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.49
| Source | Headline |
|---|---|
|
Wall Street Analysts Believe Alpha Teknova (TKNO) Could Rally 35.45%: Here's is How to Trade
The mean of analysts' price targets for Alpha Teknova (TKNO) points to a 35.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com - 2026-08-10 10:57:12 |
|
Alpha Teknova Q2 Earnings Call Highlights
Alpha Teknova NASDAQ: TKNO reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company's 30-year history. The company raised its full-year revenue outlook, citing first-half performance and confidence in the second half of 2026. marketbeat.com - 2026-08-06 02:05:42 |
|
Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript
Alpha Teknova, Inc. (TKNO) Q2 2026 Earnings Call Transcript seekingalpha.com - 2026-08-05 21:00:07 |
|
Teknova Reports Second Quarter 2026 Financial Results
Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek™ custom order configurator, giving developers a faster path from preclinical to clinical manufacturing HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2026. globenewswire.com - 2026-08-05 16:01:00 |
|
Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes
HOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today launched Build-Tek™, an AI-powered custom order configurator that enables developers of therapies and diagnostics to design complex custom products and submit a request for quote in minutes. globenewswire.com - 2026-08-05 08:59:00 |
|
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Archer-Daniels Midland, Best Buy, Burlington Stores, Dell Technologies, e.l.f. Beauty, Humana, Transdigm, Vale, and More
Wall Street analysts reshuffled their ratings on Wednesday, sending some familiar names higher while punishing others with sharp target cuts. Find out which stocks got surprise upgrades and which ones analysts are now walking away from. 247wallst.com - 2026-08-05 07:59:31 |
|
Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026
HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market. globenewswire.com - 2026-07-22 16:01:00 |
